Nanjing Frontier's NSAID Patch Meets U.S. Trial Endpoints

Nanjing Frontier Biotechnologies reported its novel pain-relieving patch met trial endpoints in a US Phase II clinical test. At week two, AB001 demonstrated a statistically significant improved pain relief against placebo in patients with chronic low back pain. Frontier acquired the NSAID patch in late 2014 from ABsize of Japan. It is a prescription-strength product aimed at treating acute pain and inflammation of the joints and muscles.